Melanoma that spreads to the brain is one of the most difficult cancers to treat, with historically poor outcomes. This Phase II trial from MD Anderson Cancer Center explored whether combining two immune checkpoint inhibitors — ipilimumab (at a reduced dose) and pembrolizumab — could safely attack brain metastases while limiting side effects. Both drugs work by releasing the immune system's natural brakes, allowing it to recognize and destroy cancer cells. The lower ipilimumab dose was chosen to reduce toxicity while preserving immune activation. With 24 patients enrolled and the trial now completed, results from this study could help refine treatment protocols for a patient population with very limited options. Full outcome data are not yet publicly detailed in the abstract.
